-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Lyell Immunopharma (NASDAQ:LYEL) PT Lowered to $4.00 at Morgan Stanley
Lyell Immunopharma (NASDAQ:LYEL) PT Lowered to $4.00 at Morgan Stanley
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) had its price target trimmed by Morgan Stanley from $7.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.
A number of other analysts have also recently issued reports on LYEL. The Goldman Sachs Group cut Lyell Immunopharma from a buy rating to a neutral rating and decreased their target price for the stock from $13.00 to $7.00 in a report on Friday, November 11th. HC Wainwright decreased their price target on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th.
Get Lyell Immunopharma alerts:Lyell Immunopharma Stock Performance
Shares of NASDAQ:LYEL opened at $3.04 on Tuesday. Lyell Immunopharma has a 1 year low of $2.74 and a 1 year high of $8.74. The stock has a market capitalization of $757.95 million, a P/E ratio of -3.42 and a beta of -1.91. The stock has a 50-day simple moving average of $3.53 and a 200-day simple moving average of $5.51.
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. Lyell Immunopharma had a negative return on equity of 29.54% and a negative net margin of 660.62%. Analysts predict that Lyell Immunopharma will post -1 earnings per share for the current year.Hedge Funds Weigh In On Lyell Immunopharma
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in Lyell Immunopharma by 76.1% in the 1st quarter. Royal Bank of Canada now owns 9,114 shares of the company's stock worth $46,000 after acquiring an additional 3,940 shares during the period. Nisa Investment Advisors LLC purchased a new position in shares of Lyell Immunopharma during the 2nd quarter valued at approximately $38,000. Baillie Gifford & Co. boosted its stake in shares of Lyell Immunopharma by 0.8% during the 4th quarter. Baillie Gifford & Co. now owns 761,321 shares of the company's stock valued at $2,642,000 after buying an additional 6,216 shares during the last quarter. American International Group Inc. boosted its stake in shares of Lyell Immunopharma by 10.0% during the 2nd quarter. American International Group Inc. now owns 80,983 shares of the company's stock valued at $528,000 after buying an additional 7,338 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Lyell Immunopharma by 7.3% during the 3rd quarter. New York State Common Retirement Fund now owns 117,792 shares of the company's stock valued at $863,000 after buying an additional 8,050 shares during the last quarter. Hedge funds and other institutional investors own 45.04% of the company's stock.
Lyell Immunopharma Company Profile
(Get Rating)
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
Featured Stories
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
莱尔免疫瘤(纳斯达克:LYEL-GET评级)据Benzinga报道,在周二上午发布的一份报告中,摩根士丹利将其目标价从7美元下调至4美元。该经纪公司目前对该股的评级为同等权重。
其他一些分析师最近也发布了关于LYEL的报告。在11月11日星期五的一份报告中,高盛将莱尔免疫的评级从买入下调至中性,并将该股的目标价从13.00美元下调至7.00美元。在11月9日星期三的一份报告中,HC Wainwright将他们对Lyell免疫瘤的目标价从12.00美元下调至11.00美元。
到达莱尔免疫性咽炎警报:莱尔免疫公司股票表现
纳斯达克:LYEL周二开盘报3.04美元。莱尔免疫公司的一年低点为2.74美元,一年高位为8.74美元。该股市值为7.5795亿美元,市盈率为-3.42,贝塔系数为-1.91。该股的50日简单移动均线切入位为3.53美元,200日简单移动均线切入位为5.51美元。
莱尔免疫公司(纳斯达克代码:LYEL-GET Rating)最近一次发布收益报告是在11月8日(星期二)。该公司公布本季度每股收益(EPS)为0.28美元,比分析师普遍预期的0.34美元高出0.06美元。莱尔免疫公司的净资产回报率为负29.54%,净利润率为负660.62%。分析师预测,莱尔免疫公司本年度的每股收益将为1美元。对冲基金参与了莱尔免疫瘤的研究
一些机构投资者和对冲基金最近买卖了该股的股票。加拿大皇家银行在第一季度增持了76.1%的莱尔免疫。加拿大皇家银行在此期间增持了3940股,现在持有该公司9,114股股票,价值46,000美元。NISA投资顾问公司在第二季度购买了莱尔免疫公司的新股票,价值约3.8万美元。去年第四季度,Baillie Gifford&Co.将其在莱尔免疫公司的持股比例提高了0.8%。Baillie Gifford&Co.现在持有761,321股该公司股票,价值2,642,000美元,该公司在上个季度又购买了6,216股。美国国际集团(American International Group Inc.)在第二季度增持了莱尔免疫的股份10.0%。美国国际集团目前持有该公司80,983股股票,价值528,000美元,在上个季度又购买了7,338股。最后,纽约州共同退休基金在第三季度将其在莱尔免疫公司的股份增加了7.3%。纽约州共同退休基金现在拥有117,792股该公司的股票,价值863,000美元,在上个季度又购买了8,050股。对冲基金和其他机构投资者持有该公司45.04%的股份。
莱尔免疫公司简介
(获取评级)
莱尔免疫公司是一家T细胞再编程公司,致力于为实体肿瘤患者开发T细胞疗法。该公司使用技术平台开发疗法,例如Gen-R,一种克服T细胞衰竭的体外遗传重新编程技术;以及Epi-R,一种体外表观遗传重新编程技术,以产生具有持久干细胞特性的T细胞群体。
专题报道
- 免费获取StockNews.com关于Lyell免疫瘤的研究报告(LYEL)
- Crane Holdings什么时候起飞?
- 现在是时候积极投资国防类股了吗?
- 2023年响亮登场的3只零售股
- EVGO股票充值,驾驭电动汽车普及浪潮
- 高通从分析师那里得到了提振,但现在是收购的时候了吗?
接受《莱尔免疫瘤日报》的新闻和评级-在下面输入您的电子邮件地址,以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Lyell免疫疗法和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧